Skip to main content

2 Result(s)

within Daniel Sung-Ho Cho Remove this filter

and

  1. No Access

    Article

    Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea

    The DAPA-HF and DELIVER trials demonstrated the clinical benefits of dapagliflozin in heart failure (HF) patients across the entire ejection fraction (EF) spectrum. However, further investigation is needed for...

    Eui-Soon Kim, Sun-Kyeong Park… in American Journal of Cardiovascular Drugs (2024)

  2. No Access

    Article

    Systematic Review of the Economic Evaluation of Sodium–Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure

    Sodium–glucose cotransporter-2 (SGLT2) inhibitors have been recently used as therapeutic agents for type 2 diabetes mellitus. Recent clinical trials have shown that they are beneficial for reducing the risk of...

    Kyungae Nam, Daniel Sung-Ho Cho, Hyunji Kim, Byung** Kwon… in Clinical Drug Investigation (2023)